StreetInsider.com News Articles

Form SCHEDULE 13D/A Entrada Therapeutics, Filed by: MPM BioVentures 2014, L.P.

Thu, 10 Sep 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260910/27048791.html

Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program

Thu, 10 Sep 2026 07:00:00 -0400

-- Announced following World Duchenne Awareness Day on September 7, grants are designed to support projects bridging healthcare disparities across the global Duchenne community --

BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the recipients of its 2026 DREAMS Grant Program: a competitive annual program that awards two $50,000 grants in support of projects working to better identify, understand and reach members of the Duchenne muscular dystrophy community who are currently underrepresented or underserved. An Independent Grant Review Committee, consisting of neuromuscular specialists, patient advocates and health equity advocates, is

Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program

Thu, 10 Sep 2026 07:00:00 -0400

-- Announced following World Duchenne Awareness Day on September 7, grants are designed to support projects bridging healthcare disparities across the global Duchenne community --

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 02 Sep 2026 16:30:00 -0400

BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 61,365 restricted stock units (“RSUs”) and options to purchase 19,425 shares of the Company’s common stock to eight newly-hired non-executive employees under the Company’s 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of September 1, 2026. The options have an exercise price of $7.07 per share, which is equal to the closing price of the Company's common stock on August 31, 2026. The inducement grants were previously approved by the Compensation Committee of the Company’s Board

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 02 Sep 2026 16:30:00 -0400

Form 4 Entrada Therapeutics, For: Aug 24 Filed by: MPM BIOVENTURES 2018, L.P.

Wed, 26 Aug 2026 21:28:00 -0400

si-local-file:///var/storage/secattach/20260826/26983319.html

Form 4 Entrada Therapeutics, For: Aug 24 Filed by: MPM BIOVENTURES 2018, L.P.

Wed, 26 Aug 2026 21:28:00 -0400

si-local-file:///var/storage/secattach/20260826/26983319.html

Form 4 Entrada Therapeutics, For: Aug 24 Filed by: GADICKE ANSBERT

Wed, 26 Aug 2026 21:28:00 -0400

si-local-file:///var/storage/secattach/20260826/26983320.html

Form 4 Entrada Therapeutics, For: Aug 24 Filed by: GADICKE ANSBERT

Wed, 26 Aug 2026 21:28:00 -0400

si-local-file:///var/storage/secattach/20260826/26983320.html

Form SCHEDULE 13G/A Entrada Therapeutics, Filed by: TCG Crossover GP I, LLC

Fri, 14 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260814/26931001.html

Form SCHEDULE 13G/A Entrada Therapeutics, Filed by: TCG Crossover GP I, LLC

Fri, 14 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260814/26931001.html

Form 4 Entrada Therapeutics, For: Aug 06 Filed by: PARMAR KUSH

Mon, 10 Aug 2026 19:55:00 -0400

si-local-file:///var/storage/secattach/20260810/26899625.html

Form 4 Entrada Therapeutics, For: Aug 06 Filed by: PARMAR KUSH

Mon, 10 Aug 2026 19:55:00 -0400

si-local-file:///var/storage/secattach/20260810/26899625.html

Form 4 Entrada Therapeutics, For: Aug 06 Filed by: ROCKLAGE SCOTT M

Mon, 10 Aug 2026 19:53:00 -0400

si-local-file:///var/storage/secattach/20260810/26899624.html

Form 4 Entrada Therapeutics, For: Aug 06 Filed by: ROCKLAGE SCOTT M

Mon, 10 Aug 2026 19:53:00 -0400

si-local-file:///var/storage/secattach/20260810/26899624.html

Form 144/A Entrada Therapeutics, Filed by: 5AM Ventures V, L.P.

Mon, 10 Aug 2026 19:50:00 -0400

si-local-file:///var/storage/secattach/20260810/26899620.html

Form 144/A Entrada Therapeutics, Filed by: 5AM Ventures V, L.P.

Mon, 10 Aug 2026 19:50:00 -0400

si-local-file:///var/storage/secattach/20260810/26899620.html

Form 10-Q Entrada Therapeutics, For: Jun 30

Wed, 05 Aug 2026 07:11:00 -0400

si-local-file:///var/storage/secattach/20260805/26870200.html

Form 10-Q Entrada Therapeutics, For: Jun 30

Wed, 05 Aug 2026 07:11:00 -0400

si-local-file:///var/storage/secattach/20260805/26870200.html

Form 8-K Entrada Therapeutics, For: Aug 05

Wed, 05 Aug 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20260805/26870124.html

Form 8-K Entrada Therapeutics, For: Aug 05

Wed, 05 Aug 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20260805/26870124.html

Entrada Therapeutics Reports Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 07:00:00 -0400

-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 --

-- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 --

-- Company to report ELEVATE-45-201 Cohort 1 data in October 2026 --

-- ELEVATE-45-201 Cohort 2 dosing ongoing at the increased dose of 10 mg/kg with data expected in H1 2027 --

-- Vertex to report VX-670 Phase 1/2 data in people living with DM1 in H2 2026 --

BOSTON,

Entrada Therapeutics Reports Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 07:00:00 -0400

-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 --

-- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 --

-- Company to report ELEVATE-45-201 Cohort 1 data in October 2026 --

-- ELEVATE-45-201 Cohort 2 dosing ongoing at the increased dose of 10 mg/kg with data expected in H1 2027 --

-- Vertex to report VX-670 Phase 1/2 data in people living with DM1 in H2 2026 --

BOSTON,

Form 4 Entrada Therapeutics, For: Jul 30 Filed by: ROCKLAGE SCOTT M

Mon, 03 Aug 2026 17:33:00 -0400

si-local-file:///var/storage/secattach/20260803/26859526.html

Form 4 Entrada Therapeutics, For: Jul 30 Filed by: ROCKLAGE SCOTT M

Mon, 03 Aug 2026 17:33:00 -0400

si-local-file:///var/storage/secattach/20260803/26859526.html